Physician profile
Amanda Eileen Harpring
NPI 1205138757
$2,269.58
in general payments reported to CMS, 2019-2025
20 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $151 · 2021: $530 · 2022: $501 · 2023: $228 · 2024: $252 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $709.87 | 2019-2025 | |
| Leo Pharma INC. | $223.67 | 2020-2025 | Adbry |
| Galderma Laboratories, L.P. | $203.79 | 2019-2024 | Dysport |
| Sun Pharmaceutical Industries INC. | $167.70 | 2020-2025 | Ilumya |
| Epi Health, LLC | $134.17 | 2020-2022 | |
| Janssen Biotech, INC. | $122.92 | 2021-2023 | Simponi, Simponi Aria, Remicade |
| Amgen INC. | $106.56 | 2019-2025 | Otezla, Enbrel |
| Allergan, INC. | $102.04 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $76.59 | 2021-2024 | |
| Genzyme Corporation | $75.91 | 2021-2022 | |
| Incyte Corporation | $67.48 | 2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $59.96 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.67 | 2023-2024 | Spevigo |
| Ucb, INC. | $39.39 | 2019-2021 | |
| Almirall LLC | $27.72 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $22.88 | 2024 | Venclose Maven Catheter |
| Biofrontera INC. | $20.90 | 2019 | |
| Verrica Pharmaceuticals INC. | $19.14 | 2025 | Ycanth |
| Lilly USA, LLC | $16.24 | 2021 | |
| Celgene Corporation | $15.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Harpring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.